| Date | Time | Source | Headline | Symbol | Company |
| 05/17/2024 | 8:00AM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |
| 05/17/2024 | 8:00AM | GlobeNewswire Inc. | Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine | AMEX:OGEN | Oragenics Inc |
| 05/16/2024 | 8:00AM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |
| 05/16/2024 | 8:00AM | GlobeNewswire Inc. | Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial | AMEX:OGEN | Oragenics Inc |
| 05/15/2024 | 1:00PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | AMEX:OGEN | Oragenics Inc |
| 05/07/2024 | 8:14AM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |
| 05/07/2024 | 8:00AM | GlobeNewswire Inc. | Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia | AMEX:OGEN | Oragenics Inc |
| 04/19/2024 | 5:50PM | Business Wire | Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards | AMEX:OGEN | Oragenics Inc |
| 04/01/2024 | 9:05AM | Business Wire | Oragenics, Inc. Files 10K and Provides Company Update | AMEX:OGEN | Oragenics Inc |
| 03/18/2024 | 7:00AM | Business Wire | Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion | AMEX:OGEN | Oragenics Inc |
| 03/06/2024 | 4:24PM | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | AMEX:OGEN | Oragenics Inc |
| 03/05/2024 | 7:45AM | Business Wire | Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion | AMEX:OGEN | Oragenics Inc |
| 03/01/2024 | 4:04PM | Business Wire | Oragenics Announces Closing of Public Offering | AMEX:OGEN | Oragenics Inc |
| 02/29/2024 | 4:41PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | AMEX:OGEN | Oragenics Inc |
| 02/28/2024 | 9:03AM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |
| 02/27/2024 | 9:25PM | Business Wire | Oragenics Announces Pricing of Public Offering | AMEX:OGEN | Oragenics Inc |
| 02/27/2024 | 5:09PM | Edgar (US Regulatory) | Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses | AMEX:OGEN | Oragenics Inc |
| 02/27/2024 | 5:04PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | AMEX:OGEN | Oragenics Inc |
| 02/27/2024 | 4:33PM | Business Wire | Oragenics Announces Proposed Public Offering | AMEX:OGEN | Oragenics Inc |
| 02/12/2024 | 8:06PM | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | AMEX:OGEN | Oragenics Inc |
| 02/12/2024 | 4:45PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |
| 02/12/2024 | 4:41PM | Business Wire | Oragenics, Inc. Announces Leadership Transition | AMEX:OGEN | Oragenics Inc |
| 02/07/2024 | 8:00AM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |
| 02/07/2024 | 8:00AM | Business Wire | Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement | AMEX:OGEN | Oragenics Inc |
| 02/05/2024 | 8:00AM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |
| 02/05/2024 | 8:00AM | Business Wire | Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion | AMEX:OGEN | Oragenics Inc |
| 01/23/2024 | 5:34PM | Business Wire | Oragenics Announces Termination of At-The-Market Offering Program | AMEX:OGEN | Oragenics Inc |
| 01/23/2024 | 5:18PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |
| 01/22/2024 | 5:30PM | Edgar (US Regulatory) | Form 5 - Annual statement of changes in beneficial ownership of securities | AMEX:OGEN | Oragenics Inc |
| 01/16/2024 | 9:10AM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:OGEN | Oragenics Inc |